... ich hatte auch gestern nachgefragt, und hier ist die Antwort (zumindest schreibt er ja wenigstens das selbe) ;-)))
Thank you for your email. You are correct ? the Company?s council is working with the Frankfurt Exchange and the Company?s market maker now to rectify the situation. Our council has been told that this happened because of an issue with the share clearing mechanism of the Company in Germany. The difficulty we have is that public companies do not have a direct relationship with the clearing companies and so we need to rely on the Frankfurt exchange and market maker to deal with the clearing company on behalf of ChroMedX to clarify what the issue stems from and how to solve it ? of course this process is very slow, waiting on parties to communicate with each other. The Frankfurt Exchange and marker maker are being very helpful.
Our council has communicated with Bafin about the issue and continues to communicate with the Frankfurt Exchange while working to rectify this situation. It is very frustrating as the Company?s council and the Frankfurt Exchange have not dealt with a situation like this before, so there is no standard operating procedure. For instance, the Company was back trading on the Tradegate Exchange for several days and the exchange group and the Company?s market maker has no reason for this, or idea as to how this happened. The Company has been trading in Germany since its inception in 2014 and the shell had been listed in Frankfurt for over 15 years. Our investors in Europe are extremely important to the Company and have been very supportive throughout the years. ChroMedX will rectify this issue by whatever means necessary. If the Company has to apply for a brand new listing then that?s what it will do, whatever it takes to rectify this situation will be done. We will not let our investors down. The system in Germany is not as straightforward as it is in other markets and it is costing ChroMedX a lot of money now to get answers and work towards a solution but our council is focused on getting this rectified as soon as possible. It is unfortunate that there are negative rumors at this point but I can understand this as to how confusing this situation has been. ChroMedX as a Company is in better position than ever before. The Company?s management and techno-commercial teams are world class and I expect this to not only accelerate and maximize the value of the HemoPalm but also lead to other significant value building opportunities for all stakeholders. Thank you again for your email. Please do not hesitate to reach out directly if you have any other questions. Clark W. Clark Kent President ChroMedX Corp.
|